<DOC>
	<DOCNO>NCT01333449</DOCNO>
	<brief_summary>Allogeneic blood stem cell transplant remain potential curative treatment myelodysplastic syndrome ( MDS ) date . Pre-transplant induction chemotherapy leukemia-type regimen associate significant toxicity even death . The hypomethylating agent decitabine 5-azacytidine show study cause improve hematologic parameter partial complete response patient high risk MDS compare standard therapy . In contrast leukemia-type chemotherapy , decitabine associate relatively low risk toxicity . We therefore propose treat transplant-eligible MDS patient Decitabine induction therapy bridge transplant . Hypothesis : 1 . Decitabine able reduce disease burden measure blood marrow blast count prior allogeneic hematopoietic stem cell transplant 5 % . 2 . Decitabine well-tolerated patient high-risk MDS safe induction agent bridge prior allogeneic transplant transplant-eligible patient .</brief_summary>
	<brief_title>Study Decitabine Induction Prior Allogeneic Hematopoietic Cell Transplant Newly Diagnosed MDS Patients</brief_title>
	<detailed_description>Primary endpoint : 1. safety tolerability Decitabine prior transplant ( assessed occurence non-hematologic toxicity grade 3 defined CTC grading ) 2. reduction pre-transplant disease burden ability achieve blast &lt; 5 % bone marrow peripheral blood Secondary endpoint : 1 . Proportion patient suitable donor able proceed allogeneic hematopoietic cell transplant . 2 . Non-relapse mortality 3. time neutrophil engraftment 4 . Overall survival disease-free survival . Patients receive Decitabine blast &lt; 5 % achieve , suitable HLA-matched donor umbilical cord blood available maximum 6 cycle . Patient progress therapy unable find donor 6 cycle remove protocol . The method , condition regimen choice donor determine base patient 's age functional status , transplant physician 's discretion . The available regimen standardize within center</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Newly diagnose MDS patient age 21 65 year belong follow category : refractory cytopenia multilineage dysplasia ( RCMD ) without ring sideroblast ( i.e . RCMD RCMDRS ) , refractory anemia excess blasts1 ( RAEB1 ) RAEB2 prognostic score IPSS ( international prognostic score system ) Int2 IPSShigh WPSS ( WHO prognostic score system ) 3 2 . Therapyrelated MDS IPSS Int2 WPSS 3 3 . Acceptable cardiac function MUGA Echocardiography leave ventricular ejection fraction 40 % 4 . Acceptable lung function : FEV1 &gt; 70 % predict , DLCO &gt; 60 % predict 5 . Acceptable renal function : CCT &gt; 50ml/min 6 . Acceptable liver function : abnormality bilirubin transaminase &gt; 2times upper limit normal 7 . Performance status ECOG 2 HCTspecific Comorbidity Index &lt; 3 1 . Any comorbidity MDS limit lifeexpectancy &lt; 3mth 2 . Diagnosis active cancer squamous cell carcinoma , basal cell carcinoma carcinomainsitu 1 2 cervix 3 . Presence active infection control 4 . Receipt 5azacytidine induction chemotherapy MDS/AML 5 . Patients keen explore allogeneic HCT part curative treatment plan 6 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Decitabine</keyword>
	<keyword>MDS , myelodysplastic syndrome</keyword>
	<keyword>prospective open label , phaseII</keyword>
	<keyword>Allogeneic Hematopoietic cell transplant</keyword>
</DOC>